Predict your next investment

HEALTHCARE | Drug Discovery
hepregen.com

See what CB Insights has to offer

Founded Year

2007

Stage

Merger | Merged

Total Raised

$6.81M

About Hepregen

Hepregen, a spinout of MIT, is developing a platform to reduce the liver toxicity caused by approved drugs. The platform is based on technology developed by Sangeeta Bhatia, an associate professor in the Harvard-MIT Division of Health Sciences and Technology (HST) and MIT's Department of Electrical Engineering and Computer Science. The technology is based on engineered "miniature micro liver cells."

Hepregen Headquarter Location

200 Boston Ave Suite 150

Medford, Massachusetts, 02155,

United States

Latest Hepregen News

Hepregen Corporation (Ascendance Biotechnology)

Jun 24, 2020

MIT Deshpande Center 2008 | Healthcare Hepregen Corporation is developing bioengineered solutions for drug development, including a platform for advanced toxicity screening and drug discovery. With its high fidelity model of the human liver, Hepregen's bioengineered solution may provide improved predictivity of how drugs will affect the liver once in humans. For the story of the Deshpande Center project that became Hepregen Corporation, see Case Studies . This company is a spinout of the 2006 project , Human liver models for faster, safer drug development.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Hepregen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Hepregen is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

5,731 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Hepregen Patents

Hepregen has filed 4 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Abandoned drugs
  • Cell biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/26/2016

6/30/2020

Clusters of differentiation, Transcription factors, Cell biology, Human cells, Immunology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/26/2016

00/00/0000

00/00/0000

00/00/0000

Grant Date

6/30/2020

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Clusters of differentiation, Transcription factors, Cell biology, Human cells, Immunology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.